Faber Logo Skip to main content
Man reviewing graphs

Projects We Work On

Private Financing


If you're the founder or CFO of a science-based startup, you need to understand your financing options. You’re looking for a law firm that can introduce you to venture capitalists and other funding sources, and at the same time, you want legal counsel that understands your company’s potential in order to strike a deal that acknowledges the value you’re creating and protects your interests.

We work with you to structure financing that aligns your interests with those of investors, while fairly balancing control and decision-making.


At Faber, we’ve represented 2,000+ clients in life science, healthcare IT, medical devices and engineering technology. We often act as corporate counsel and provide legal guidance to management and boards of directors alike on the full range of private financing options.

We have strong relationships with the investor groups that focus on these verticals and have advised many of them on their own transactions.

Based on your circumstances, we’ll advise you on the optimal source of financing, including:

  • Founders’ agreements
  • Angel financing
  • Venture capital
  • Foundation grants
  • Government investment programs
  • Venture debt
  • Equipment financing and capital leasing
  • Conventional bank financing
  • Royalty financing
  • Shareholder agreements
  • Equity compensation

We have been actively involved in preparing model documents published by the National Venture Capital Association. But we also recognize that successful deals are about more than contract terms. Faber’s sector focus prepares us to understand your opportunities and challenges.

Related Transactions

Previous Page
Next Page
NextPoint Therapeutics, Inc. Logo

NextPoint Therapeutics, Inc.

Series B Financing - $80 million

NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.  Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Existing investors that took part in the financing include MPM Capital Management and Dana-Farber Cancer Institute

6 Dimensions Capital Logo

6 Dimensions Capital

VC Investments

Equity investments in multiple portfolio companies, including Hibercell

Epalex Corporation Logo

Epalex Corporation

Series A-3 Financing

Series A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs

Praeventix, Inc. Logo

Praeventix, Inc.

Private Investment

Private Investment from Tellus BioVentures

Vizgen, Inc. Logo

Vizgen, Inc.

Series C Financing

Vizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors

Press Release
Vernal Biosciences, Inc. Logo

Vernal Biosciences, Inc.

Series A Financing

Vernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership

Press Release
Artax Biopharma, Inc. Logo

Artax Biopharma, Inc. + Advent Life Sciences Fund II LP

Series B Financing (Series B4)

Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly

Press Release
Dianthus Therapeutics OpCo, Inc. Logo

Dianthus Therapeutics OpCo, Inc.

Series A Financing

Dianthus raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors

Press Release
Summation Bio, Inc. Logo

Summation Bio, Inc.

Series A Financing

Summation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors

Aliada Therapeutics, Inc. Logo

Aliada Therapeutics, Inc.

Series Seed-1 Financing

Counsel to Aliada in completing its Series Seed financing, with investment from Johnson & Johnson Innovation, RA Capital, OrbiMed and Sanofi Ventures

Vizgen, Inc. Logo

Vizgen, Inc.

Series B Financing

Vizgen raises Series B equity funding from Northpond Ventures LP, ARCH Venture Fund X, L.P., Novalis LifeSciences LLC, Tao Capital Management, Pura Vida Investments and other current investors

Press Release
GV (Google Ventures) Logo

GV (Google Ventures) + Hyperfine Research

Series D Financing

Faber has assisted GV in Hyperfine Research’s $90M Series D Financing

Press Release
5AM Venture Management LLC Logo

5AM Venture Management LLC + Pear Therapeutics, Inc.

Series D Financing

Series D Financing of Pear Therapeutics, Inc.

Press Release
Series B Financing

Faber has assisted RA Capital as the co-lead in a $110 million Series B Financing in Vor Biopharma

Press Release
Viridian Therapeutics, Inc. Logo

Viridian Therapeutics, Inc.

Series Seed Financing

Series Seed Preferred Stock Financing led by Fairmount Funds

Related Services

Previous Page
Next Page
This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.